nodes	percent_of_prediction	percent_of_DWPC	metapath
Niflumic Acid—PLA2G1B—Betamethasone—multiple sclerosis	0.442	0.491	CbGbCtD
Niflumic Acid—PLA2G1B—Dexamethasone—multiple sclerosis	0.257	0.285	CbGbCtD
Niflumic Acid—SLC16A1—Methotrexate—multiple sclerosis	0.0758	0.0842	CbGbCtD
Niflumic Acid—PTGS2—Triamcinolone—multiple sclerosis	0.0534	0.0593	CbGbCtD
Niflumic Acid—PTGS2—Betamethasone—multiple sclerosis	0.0458	0.0509	CbGbCtD
Niflumic Acid—PTGS2—Dexamethasone—multiple sclerosis	0.0266	0.0296	CbGbCtD
Niflumic Acid—CLCNKA—cerebellum—multiple sclerosis	0.00333	0.1	CbGeAlD
Niflumic Acid—PTGS2—leg—multiple sclerosis	0.00263	0.0792	CbGeAlD
Niflumic Acid—SLC16A7—medulla oblongata—multiple sclerosis	0.00157	0.0472	CbGeAlD
Niflumic Acid—PLA2G4A—Raltitrexed—Methotrexate—multiple sclerosis	0.00154	0.28	CbGdCrCtD
Niflumic Acid—SLC16A7—midbrain—multiple sclerosis	0.00143	0.0431	CbGeAlD
Niflumic Acid—PLA2G1B—nervous system—multiple sclerosis	0.0014	0.0421	CbGeAlD
Niflumic Acid—SLC16A1—retina—multiple sclerosis	0.00138	0.0416	CbGeAlD
Niflumic Acid—PLA2G1B—central nervous system—multiple sclerosis	0.00135	0.0405	CbGeAlD
Niflumic Acid—SLC16A7—nervous system—multiple sclerosis	0.00118	0.0355	CbGeAlD
Niflumic Acid—SLC16A7—central nervous system—multiple sclerosis	0.00113	0.0341	CbGeAlD
Niflumic Acid—PLA2G4A—medulla oblongata—multiple sclerosis	0.00113	0.0341	CbGeAlD
Niflumic Acid—SLC16A7—cerebellum—multiple sclerosis	0.00111	0.0334	CbGeAlD
Niflumic Acid—PLA2G1B—brain—multiple sclerosis	0.00107	0.0322	CbGeAlD
Niflumic Acid—PLA2G4A—midbrain—multiple sclerosis	0.00104	0.0312	CbGeAlD
Niflumic Acid—PLA2G4A—spinal cord—multiple sclerosis	0.00101	0.0304	CbGeAlD
Niflumic Acid—SLC16A1—medulla oblongata—multiple sclerosis	0.000998	0.03	CbGeAlD
Niflumic Acid—SLC16A1—midbrain—multiple sclerosis	0.000912	0.0275	CbGeAlD
Niflumic Acid—SLC16A7—brain—multiple sclerosis	0.000901	0.0271	CbGeAlD
Niflumic Acid—SLC16A1—spinal cord—multiple sclerosis	0.00089	0.0268	CbGeAlD
Niflumic Acid—PLA2G4A—nervous system—multiple sclerosis	0.000852	0.0256	CbGeAlD
Niflumic Acid—PLA2G4A—central nervous system—multiple sclerosis	0.00082	0.0247	CbGeAlD
Niflumic Acid—SLC16A1—nervous system—multiple sclerosis	0.00075	0.0226	CbGeAlD
Niflumic Acid—SLC16A1—central nervous system—multiple sclerosis	0.000722	0.0217	CbGeAlD
Niflumic Acid—SLC16A1—cerebellum—multiple sclerosis	0.000706	0.0212	CbGeAlD
Niflumic Acid—PLA2G4A—brain—multiple sclerosis	0.000651	0.0196	CbGeAlD
Niflumic Acid—SLC16A1—brain—multiple sclerosis	0.000573	0.0172	CbGeAlD
Niflumic Acid—PTGS2—medulla oblongata—multiple sclerosis	0.000428	0.0129	CbGeAlD
Niflumic Acid—PTGS2—Fluocinonide—Methylprednisolone—multiple sclerosis	0.000428	0.0775	CbGdCrCtD
Niflumic Acid—PTGS2—Fluocinonide—Betamethasone—multiple sclerosis	0.000421	0.0762	CbGdCrCtD
Niflumic Acid—PTGS2—Fluocinonide—Dexamethasone—multiple sclerosis	0.000421	0.0762	CbGdCrCtD
Niflumic Acid—PTGS2—Fluocinonide—Triamcinolone—multiple sclerosis	0.000411	0.0745	CbGdCrCtD
Niflumic Acid—PTGS1—spinal cord—multiple sclerosis	0.000399	0.012	CbGeAlD
Niflumic Acid—PTGS2—midbrain—multiple sclerosis	0.000391	0.0118	CbGeAlD
Niflumic Acid—PTGS2—spinal cord—multiple sclerosis	0.000382	0.0115	CbGeAlD
Niflumic Acid—PTGS1—nervous system—multiple sclerosis	0.000336	0.0101	CbGeAlD
Niflumic Acid—PTGS1—central nervous system—multiple sclerosis	0.000324	0.00975	CbGeAlD
Niflumic Acid—PTGS2—nervous system—multiple sclerosis	0.000322	0.00968	CbGeAlD
Niflumic Acid—PTGS2—central nervous system—multiple sclerosis	0.00031	0.00932	CbGeAlD
Niflumic Acid—PTGS2—cerebellum—multiple sclerosis	0.000303	0.0091	CbGeAlD
Niflumic Acid—PTGS2—Fluticasone Propionate—Methylprednisolone—multiple sclerosis	0.000258	0.0467	CbGdCrCtD
Niflumic Acid—PTGS1—brain—multiple sclerosis	0.000257	0.00774	CbGeAlD
Niflumic Acid—PTGS2—Fluticasone Propionate—Betamethasone—multiple sclerosis	0.000254	0.046	CbGdCrCtD
Niflumic Acid—PTGS2—Fluticasone Propionate—Dexamethasone—multiple sclerosis	0.000254	0.046	CbGdCrCtD
Niflumic Acid—PTGS2—Fluticasone Propionate—Triamcinolone—multiple sclerosis	0.000248	0.045	CbGdCrCtD
Niflumic Acid—PTGS2—brain—multiple sclerosis	0.000246	0.0074	CbGeAlD
Niflumic Acid—PLA2G4A—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000165	0.00273	CbGpPWpGaD
Niflumic Acid—SLC16A1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000165	0.00272	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	0.000164	0.00272	CbGpPWpGaD
Niflumic Acid—PLA2G4A—PLC beta mediated events—MAPK1—multiple sclerosis	0.000163	0.00269	CbGpPWpGaD
Niflumic Acid—PTGS2—Overview of nanoparticle effects—TNF—multiple sclerosis	0.000163	0.00269	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—CYP24A1—multiple sclerosis	0.000162	0.00267	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—CYP27B1—multiple sclerosis	0.000162	0.00267	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.000161	0.00266	CbGpPWpGaD
Niflumic Acid—PLA2G4A—G-protein mediated events—MAPK1—multiple sclerosis	0.00016	0.00264	CbGpPWpGaD
Niflumic Acid—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—multiple sclerosis	0.000159	0.00263	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000158	0.00261	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—PLEK—multiple sclerosis	0.000148	0.00245	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—GPC5—multiple sclerosis	0.000148	0.00244	CbGpPWpGaD
Niflumic Acid—PLA2G4A—AGE/RAGE pathway—MMP9—multiple sclerosis	0.000146	0.00241	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—CCR2—multiple sclerosis	0.000139	0.0023	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000137	0.00226	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000137	0.00226	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Betamethasone—Methylprednisolone—multiple sclerosis	0.000135	0.0244	CbGdCrCtD
Niflumic Acid—PLA2G4A—Dexamethasone—Methylprednisolone—multiple sclerosis	0.000135	0.0244	CbGdCrCtD
Niflumic Acid—SLC16A1—Metabolism—SRM—multiple sclerosis	0.000134	0.00222	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—SELE—multiple sclerosis	0.000134	0.00222	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Dexamethasone—Betamethasone—multiple sclerosis	0.000133	0.024	CbGdCrCtD
Niflumic Acid—PLA2G4A—Betamethasone—Dexamethasone—multiple sclerosis	0.000133	0.024	CbGdCrCtD
Niflumic Acid—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	0.000133	0.0022	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	0.000132	0.00218	CbGpPWpGaD
Niflumic Acid—PTGS2—Overview of nanoparticle effects—IL6—multiple sclerosis	0.000131	0.00217	CbGpPWpGaD
Niflumic Acid—SLC16A1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	0.00013	0.00215	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Dexamethasone—Triamcinolone—multiple sclerosis	0.00013	0.0235	CbGdCrCtD
Niflumic Acid—PLA2G4A—Betamethasone—Triamcinolone—multiple sclerosis	0.00013	0.0235	CbGdCrCtD
Niflumic Acid—PLA2G4A—AGE/RAGE pathway—STAT3—multiple sclerosis	0.000129	0.00214	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—MAPK1—multiple sclerosis	0.000125	0.00207	CbGpPWpGaD
Niflumic Acid—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	0.000124	0.00205	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Betamethasone—Prednisone—multiple sclerosis	0.000123	0.0223	CbGdCrCtD
Niflumic Acid—PLA2G4A—Dexamethasone—Prednisone—multiple sclerosis	0.000123	0.0223	CbGdCrCtD
Niflumic Acid—PTGS1—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000123	0.00203	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—RRM1—multiple sclerosis	0.000122	0.00203	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Endothelins—MAPK1—multiple sclerosis	0.000122	0.00202	CbGpPWpGaD
Niflumic Acid—PTGS1—Selenium Micronutrient Network—ICAM1—multiple sclerosis	0.000122	0.00202	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Dexamethasone—Prednisolone—multiple sclerosis	0.00012	0.0218	CbGdCrCtD
Niflumic Acid—PLA2G4A—Betamethasone—Prednisolone—multiple sclerosis	0.00012	0.0218	CbGdCrCtD
Niflumic Acid—PLA2G4A—AGE/RAGE pathway—MAPK1—multiple sclerosis	0.000118	0.00195	CbGpPWpGaD
Niflumic Acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—multiple sclerosis	0.000116	0.00192	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—CXCL10—multiple sclerosis	0.000116	0.00191	CbGpPWpGaD
Niflumic Acid—SLC16A1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	0.000115	0.0019	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	0.000113	0.00187	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000111	0.00184	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000111	0.00184	CbGpPWpGaD
Niflumic Acid—PTGS1—Selenium Micronutrient Network—CCL2—multiple sclerosis	0.000109	0.00181	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—SRM—multiple sclerosis	0.000104	0.00173	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—SELE—multiple sclerosis	0.000104	0.00172	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—BDNF—multiple sclerosis	0.000104	0.00172	CbGpPWpGaD
Niflumic Acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—multiple sclerosis	0.000103	0.0017	CbGpPWpGaD
Niflumic Acid—PTGS1—Selenium Micronutrient Network—ALB—multiple sclerosis	0.000102	0.00168	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Opioid Signalling—MAPK1—multiple sclerosis	9.99e-05	0.00165	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Platelet activation, signaling and aggregation—IL2RA—multiple sclerosis	9.98e-05	0.00165	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—S1PR1—multiple sclerosis	9.78e-05	0.00162	CbGpPWpGaD
Niflumic Acid—SLC16A7—Transmembrane transport of small molecules—ALB—multiple sclerosis	9.7e-05	0.0016	CbGpPWpGaD
Niflumic Acid—PTGS2—Selenium Micronutrient Network—ICAM1—multiple sclerosis	9.69e-05	0.0016	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—ITGA4—multiple sclerosis	9.68e-05	0.0016	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—IL4—multiple sclerosis	9.65e-05	0.0016	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—IFNB1—multiple sclerosis	9.61e-05	0.00159	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	9.5e-05	0.00157	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—CYP27B1—multiple sclerosis	9.45e-05	0.00156	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—CYP24A1—multiple sclerosis	9.45e-05	0.00156	CbGpPWpGaD
Niflumic Acid—PTGS1—Selenium Micronutrient Network—IFNG—multiple sclerosis	9.29e-05	0.00154	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	8.85e-05	0.00146	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	8.85e-05	0.00146	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	8.8e-05	0.00146	CbGpPWpGaD
Niflumic Acid—PTGS2—Selenium Micronutrient Network—CCL2—multiple sclerosis	8.67e-05	0.00143	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—SRM—multiple sclerosis	8.65e-05	0.00143	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—GPC5—multiple sclerosis	8.65e-05	0.00143	CbGpPWpGaD
Niflumic Acid—PTGS2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	8.61e-05	0.00142	CbGpPWpGaD
Niflumic Acid—PTGS2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	8.42e-05	0.00139	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—RGS1—multiple sclerosis	8.32e-05	0.00138	CbGpPWpGaD
Niflumic Acid—PTGS1—Selenium Micronutrient Network—IL1B—multiple sclerosis	8.29e-05	0.00137	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	8.16e-05	0.00135	CbGpPWpGaD
Niflumic Acid—SLC16A1—SLC-mediated transmembrane transport—ALB—multiple sclerosis	8.15e-05	0.00135	CbGpPWpGaD
Niflumic Acid—PTGS2—Selenium Micronutrient Network—ALB—multiple sclerosis	8.08e-05	0.00134	CbGpPWpGaD
Niflumic Acid—PTGS2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	8.02e-05	0.00133	CbGpPWpGaD
Niflumic Acid—UGT1A9—Biological oxidations—POMC—multiple sclerosis	8.01e-05	0.00133	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—TLR4—multiple sclerosis	7.99e-05	0.00132	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—GPR65—multiple sclerosis	7.89e-05	0.0013	CbGpPWpGaD
Niflumic Acid—PLA2G4A—PDGFR-beta signaling pathway—STAT3—multiple sclerosis	7.77e-05	0.00128	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—ICAM1—multiple sclerosis	7.66e-05	0.00127	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—LINGO1—multiple sclerosis	7.63e-05	0.00126	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—ITGA4—multiple sclerosis	7.53e-05	0.00125	CbGpPWpGaD
Niflumic Acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—multiple sclerosis	7.5e-05	0.00124	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—IFNB1—multiple sclerosis	7.47e-05	0.00124	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	7.44e-05	0.00123	CbGpPWpGaD
Niflumic Acid—PTGS2—C-MYB transcription factor network—CD4—multiple sclerosis	7.39e-05	0.00122	CbGpPWpGaD
Niflumic Acid—PTGS2—Selenium Micronutrient Network—IFNG—multiple sclerosis	7.37e-05	0.00122	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—CYP24A1—multiple sclerosis	7.35e-05	0.00122	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—CYP27B1—multiple sclerosis	7.35e-05	0.00122	CbGpPWpGaD
Niflumic Acid—PLA2G4A—PDGFR-beta signaling pathway—MYC—multiple sclerosis	7.22e-05	0.00119	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Platelet activation, signaling and aggregation—ALB—multiple sclerosis	7.21e-05	0.00119	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—CXCL13—multiple sclerosis	7.21e-05	0.00119	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—CCR1—multiple sclerosis	7.21e-05	0.00119	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	7.18e-05	0.00119	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—RRM1—multiple sclerosis	7.16e-05	0.00119	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	7.07e-05	0.00117	CbGpPWpGaD
Niflumic Acid—PLA2G4A—PDGFR-beta signaling pathway—MAPK1—multiple sclerosis	7.06e-05	0.00117	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—SRM—multiple sclerosis	7.05e-05	0.00117	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—BCHE—multiple sclerosis	7.03e-05	0.00116	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—CCL2—multiple sclerosis	6.86e-05	0.00113	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—GPC5—multiple sclerosis	6.72e-05	0.00111	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—IL2RA—multiple sclerosis	6.61e-05	0.00109	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—TAGAP—multiple sclerosis	6.61e-05	0.00109	CbGpPWpGaD
Niflumic Acid—PTGS2—Selenium Micronutrient Network—IL1B—multiple sclerosis	6.58e-05	0.00109	CbGpPWpGaD
Niflumic Acid—PTGS1—Biological oxidations—POMC—multiple sclerosis	6.53e-05	0.00108	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—CYP24A1—multiple sclerosis	6.09e-05	0.00101	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—CYP27B1—multiple sclerosis	6.09e-05	0.00101	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	6.05e-05	0.001	CbGpPWpGaD
Niflumic Acid—PTGS1—Selenium Micronutrient Network—TNF—multiple sclerosis	6.01e-05	0.000995	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	5.95e-05	0.000985	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	5.85e-05	0.000968	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—IFNG—multiple sclerosis	5.83e-05	0.000965	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—S1PR1—multiple sclerosis	5.78e-05	0.000956	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—GPC5—multiple sclerosis	5.62e-05	0.00093	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—SRM—multiple sclerosis	5.59e-05	0.000926	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—GPC5—multiple sclerosis	5.57e-05	0.000922	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—RRM1—multiple sclerosis	5.57e-05	0.000922	CbGpPWpGaD
Niflumic Acid—PTGS2—C-MYB transcription factor network—MYC—multiple sclerosis	5.32e-05	0.00088	CbGpPWpGaD
Niflumic Acid—UGT1A9—NRF2 pathway—TGFB1—multiple sclerosis	5.27e-05	0.000872	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—IL1B—multiple sclerosis	5.2e-05	0.000861	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—IL2—multiple sclerosis	5.18e-05	0.000857	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—IL2RA—multiple sclerosis	5.14e-05	0.000851	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	5.14e-05	0.000851	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—CCL3—multiple sclerosis	5.14e-05	0.00085	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	5.13e-05	0.000848	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	5.03e-05	0.000832	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—CYP27B1—multiple sclerosis	4.97e-05	0.000822	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—CYP24A1—multiple sclerosis	4.97e-05	0.000822	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—PTGER4—multiple sclerosis	4.95e-05	0.000819	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—RGS1—multiple sclerosis	4.91e-05	0.000813	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—MMP9—multiple sclerosis	4.9e-05	0.000811	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	4.85e-05	0.000803	CbGpPWpGaD
Niflumic Acid—PTGS1—Selenium Micronutrient Network—IL6—multiple sclerosis	4.85e-05	0.000803	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	4.79e-05	0.000792	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—ALB—multiple sclerosis	4.78e-05	0.000791	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—CXCR3—multiple sclerosis	4.78e-05	0.000791	CbGpPWpGaD
Niflumic Acid—PTGS2—Selenium Micronutrient Network—TNF—multiple sclerosis	4.77e-05	0.00079	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—GPR65—multiple sclerosis	4.66e-05	0.000771	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—CCR2—multiple sclerosis	4.65e-05	0.000769	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—RRM1—multiple sclerosis	4.62e-05	0.000764	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	4.56e-05	0.000755	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—GPC5—multiple sclerosis	4.54e-05	0.000751	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	4.47e-05	0.00074	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	4.32e-05	0.000715	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—GPC5—multiple sclerosis	4.3e-05	0.000712	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—CNR1—multiple sclerosis	4.29e-05	0.00071	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CXCL13—multiple sclerosis	4.26e-05	0.000705	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CCR1—multiple sclerosis	4.26e-05	0.000705	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—APOE—multiple sclerosis	4.23e-05	0.0007	CbGpPWpGaD
Niflumic Acid—SLC16A1—Transmembrane transport of small molecules—ALB—multiple sclerosis	4.14e-05	0.000685	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—BCHE—multiple sclerosis	4.11e-05	0.000681	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—MYC—multiple sclerosis	4.05e-05	0.00067	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—TGFB1—multiple sclerosis	4.04e-05	0.000669	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—MAPK1—multiple sclerosis	3.96e-05	0.000656	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—CYP24A1—multiple sclerosis	3.94e-05	0.000652	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—CYP27B1—multiple sclerosis	3.94e-05	0.000652	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—IL2—multiple sclerosis	3.88e-05	0.000642	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—CXCL10—multiple sclerosis	3.86e-05	0.000639	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.85e-05	0.000637	CbGpPWpGaD
Niflumic Acid—PTGS2—Selenium Micronutrient Network—IL6—multiple sclerosis	3.85e-05	0.000637	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—TNF—multiple sclerosis	3.77e-05	0.000625	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—RRM1—multiple sclerosis	3.76e-05	0.000623	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—ALB—multiple sclerosis	3.72e-05	0.000615	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	3.71e-05	0.000614	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—POMC—multiple sclerosis	3.63e-05	0.000601	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—GPC5—multiple sclerosis	3.61e-05	0.000597	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	3.58e-05	0.000593	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	3.39e-05	0.00056	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—CCL5—multiple sclerosis	3.32e-05	0.00055	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—ALB—multiple sclerosis	3.31e-05	0.000548	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—BCHE—multiple sclerosis	3.2e-05	0.000529	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	3.08e-05	0.000509	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—IL6—multiple sclerosis	3.05e-05	0.000504	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CCL3—multiple sclerosis	3.04e-05	0.000502	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—TGFB1—multiple sclerosis	3.02e-05	0.0005	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—IL2—multiple sclerosis	3.02e-05	0.000499	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—CCR5—multiple sclerosis	2.99e-05	0.000496	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—RRM1—multiple sclerosis	2.99e-05	0.000494	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—MAPK1—multiple sclerosis	2.97e-05	0.000491	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—IL2RA—multiple sclerosis	2.95e-05	0.000488	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—PTGER4—multiple sclerosis	2.92e-05	0.000484	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.92e-05	0.000483	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—PGR—multiple sclerosis	2.88e-05	0.000476	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CXCR3—multiple sclerosis	2.82e-05	0.000467	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.81e-05	0.000464	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—RPL5—multiple sclerosis	2.8e-05	0.000463	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CD28—multiple sclerosis	2.8e-05	0.000463	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	2.76e-05	0.000456	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	2.75e-05	0.000455	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CCR2—multiple sclerosis	2.75e-05	0.000454	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	2.7e-05	0.000446	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—SLC11A1—multiple sclerosis	2.68e-05	0.000444	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—BCHE—multiple sclerosis	2.65e-05	0.000439	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	2.57e-05	0.000425	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CNR1—multiple sclerosis	2.53e-05	0.000419	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.51e-05	0.000415	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—APOE—multiple sclerosis	2.48e-05	0.00041	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—TGFB1—multiple sclerosis	2.35e-05	0.000389	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—POMC—multiple sclerosis	2.34e-05	0.000387	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.32e-05	0.000384	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—MAPK1—multiple sclerosis	2.31e-05	0.000382	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—CCL2—multiple sclerosis	2.29e-05	0.000379	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.29e-05	0.000378	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CXCL10—multiple sclerosis	2.28e-05	0.000377	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—BCHE—multiple sclerosis	2.16e-05	0.000358	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—CD28—multiple sclerosis	2.14e-05	0.000354	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—POMC—multiple sclerosis	2.13e-05	0.000352	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—TYK2—multiple sclerosis	2.08e-05	0.000344	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CD86—multiple sclerosis	1.99e-05	0.00033	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.99e-05	0.000329	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CCL5—multiple sclerosis	1.96e-05	0.000325	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—ALB—multiple sclerosis	1.94e-05	0.000321	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—APOE—multiple sclerosis	1.92e-05	0.000319	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—SPP1—multiple sclerosis	1.82e-05	0.000301	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.82e-05	0.0003	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CCR5—multiple sclerosis	1.77e-05	0.000293	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—IL2RA—multiple sclerosis	1.74e-05	0.000289	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—IL2—multiple sclerosis	1.73e-05	0.000286	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—BCHE—multiple sclerosis	1.72e-05	0.000284	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—POMC—multiple sclerosis	1.65e-05	0.000274	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—APOE—multiple sclerosis	1.61e-05	0.000266	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—APOE—multiple sclerosis	1.6e-05	0.000264	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—CD86—multiple sclerosis	1.53e-05	0.000253	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—ALB—multiple sclerosis	1.51e-05	0.000249	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CD80—multiple sclerosis	1.46e-05	0.000241	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—POMC—multiple sclerosis	1.38e-05	0.000229	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—POMC—multiple sclerosis	1.37e-05	0.000227	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—CCR5—multiple sclerosis	1.35e-05	0.000224	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CCL2—multiple sclerosis	1.35e-05	0.000224	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—MAPK1—multiple sclerosis	1.32e-05	0.000219	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—HLA-A—multiple sclerosis	1.32e-05	0.000218	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—APOE—multiple sclerosis	1.3e-05	0.000215	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—ALB—multiple sclerosis	1.25e-05	0.000207	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—APOE—multiple sclerosis	1.23e-05	0.000204	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—TYK2—multiple sclerosis	1.23e-05	0.000203	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—POMC—multiple sclerosis	1.12e-05	0.000185	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—CD80—multiple sclerosis	1.11e-05	0.000184	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—APOE—multiple sclerosis	1.03e-05	0.000171	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—IL2—multiple sclerosis	1.02e-05	0.000169	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—ALB—multiple sclerosis	1.02e-05	0.000169	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—IL6—multiple sclerosis	1.02e-05	0.000168	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—MMP9—multiple sclerosis	9.67e-06	0.00016	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—TYK2—multiple sclerosis	9.41e-06	0.000156	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—POMC—multiple sclerosis	8.87e-06	0.000147	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—STAT3—multiple sclerosis	8.6e-06	0.000142	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—CD4—multiple sclerosis	8.51e-06	0.000141	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—ALB—multiple sclerosis	8.08e-06	0.000134	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—MYC—multiple sclerosis	7.99e-06	0.000132	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—TGFB1—multiple sclerosis	7.97e-06	0.000132	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—MAPK1—multiple sclerosis	7.82e-06	0.000129	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—STAT3—multiple sclerosis	6.59e-06	0.000109	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—MYC—multiple sclerosis	6.12e-06	0.000101	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—TGFB1—multiple sclerosis	6.11e-06	0.000101	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—IL6—multiple sclerosis	6.01e-06	9.94e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—MAPK1—multiple sclerosis	5.99e-06	9.91e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—IL6—multiple sclerosis	4.6e-06	7.61e-05	CbGpPWpGaD
